AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Revenio Group Oyj

Director's Dealing Nov 4, 2016

3236_dirs_2016-11-04_c2b17955-50f5-48c1-adfb-3398a5ea15ff.html

Director's Dealing

Open in Viewer

Opens in native device viewer

Disclosure 346596

Revenio Group Oyj - Managers' transactions

Revenio Group Corporation: Managers' transactions

Revenio Group Corporation, Stock Exchange Release, November 4, 2016 at 9.15 Managers' transactions Person subject to the notification requirement Name: Salovaara Olli-Pekka Legal Person Position: Chief Executive Officer ---------------------------------------------------------------------------- Initial Notification ---------------------------------------------------------------------------- Issuer Name: Revenio Group Oyj ---------------------------------------------------------------------------- Transaction details Transaction date: 31-10-2016 Nature of the transaction: Gift, Donation or Inheritance (Received) Instrument: Share ISIN: FI0009010912 Volume: 840 Unit price: 25,50000 Euro Aggregated transactions Volume: 840 Volume weighted average price: 25.50000 Euro For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932 DISTRIBUTION: Nasdaq Helsinki www.revenio.fi The Revenio Group in brief Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow- up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process. In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki. []

Talk to a Data Expert

Have a question? We'll get back to you promptly.